Propylene glycol is a commonly used diluent in several pharmaceutical preparations, including the sedative lorazepam. Fifty critically ill patients receiving continuous-infusion lorazepam for a minimum of 36 hours were prospectively evaluated to determine the extent of propylene glycol accumulation over time, characterize propylene glycol clearance in the presence of critical illness, and develop a pharmacokinetic model that would predict clearance based on patient-specific clinical, laboratory, and demographic factors. In this cohort, the median lorazepam infusion rate was 2.1 mg/h (0.5-18). Propylene glycol concentration correlated poorly with osmolality, osmol gap, and lactate. In all, 8 patients (16%) had significant propylene glycol accumulation (>25mg/dL). When propylene glycol concentrations were >25 mg/dL, the median lorazepam infusion rate before sample collection was higher, 6.4 (1.9-11.3) versus 2.0 (0.5-7.4) mg/h (P =.0003). A linear first-order model with interoccasion variability on clearance adjusted for total body weight and Acute Physiology and Chronic Health Evaluation II score predicted propylene glycol concentration.
Cawley MJShort-term lorazepam infusion and concern for propylene glycol toxcity: case report and review. Pharmacotherapy. 2001 ;21:1140-1144.
2.
Arbour R., Esparis B.Osmolar gap metabolic acidosis in a 60-year-old man treated for hypoxemic respiratory failure. Chest. 2000;118:545-546.
3.
Al-Khafaji AH , Dewhirst WE, Manning HLPropylene glycol toxicity associated with lorazepam infusion in a patient receiving continuous veno-venous hemofiltration with dialysis. Anesth Analg. 2002;94:1583-1585.
4.
Arroliga AC, Shehab N., McCarthy K., Gonzales JPRelationship of continuous infusion lorazepam to serum propylene glycol concnetration in critically ill adults. Crit Care Med. 2004 ;32:1709-1714.
5.
Parker MG, Fraser GL, Watson DM, Riker RRRemoval of propylene glycol and correction of increased osmolar gap by hemodialysis in a patient on high dose lorazepam infusion therapy. Intensive Care Med. 2002;2:81-84.
6.
Glasgow AM, Boeckx RL, Miller MK, MacDonald MG, August G.Hyperosmolality in small infants due to propylene glycol. Pediatrics. 1983;72:353-355.
7.
Kelner MJ, Bailey DNPropylene glycol as a cause of lactic acidosis. J Anal Toxicol . 1985;9:40-42.
8.
Tayar J., Jabbour G., Saggi SJSevere hyperosmolar metabolic acidosis due to a large dose of intravenous lorazepam. N Engl J Med. 2002;346:1253-1254.
9.
Bedicheck E. , Kirschbaum B.A case of propylene glycol toxic reaction associated with etomidate infusion. Arch Intern Med . 1991;151:2297-2298.
Reynolds HN, Teiken P., Regan ME, et al. Hyperlactatemia, increased osmolar gap, and renal dysfunction during continuous lorazepam infusion. Crit Care Med. 2000;28: 1631-1634.
12.
Neale BW, Mesler EL, Young M., Rebuck JA, Weise WJPropylene glycol-induced lactic acidosis in a patient with normal renal function: a proposed mechanism and monitoring recommendations. Ann Pharmacother . 2005; 39:1732-1736.
13.
Tuhoy KA, Nicholson WJ, Schiffman F.Agitation by sedation. Lancet. 2003 ;361:308.
14.
Demey H., Daelemans F., DeBroe ME, Bossaert L.Propylene glycol intoxication due to intravenous nitroglycerin. Lancet. 1984;1:1360.
15.
MacDonald MG , Getson PR, Glasgow AM, Miller MK, Boeckx RL, Johnson ELPropylene glycol: increase incidence of seizures in low birth weight infants. Pediatrics. 1987 ;79:622-625.
16.
Yorgin PD, Theodorou AA, Al-Uzri A., Davenport K., Boyer-Hassen LV, Johnson MIPropylene glycol-induced proximal renal tubular cell injury. Am J Kidney Dis. 1997;30:134-139.
17.
Yaucher NE, Fish JT, Smith HW, Wells JAPropylene glycol-associated renal toxicity from lorazepam infusion . Pharmacotherapy. 2003;23:1094-1099.
18.
Hayman M., Seidl EC, Ali M., Malik K.Acute tubular necrosis associated with propylene glycol from concomitant administration of intravenous lorazepam and trimethoprim-sulfamethoxazole . Pharmacotherapy. 2003; 23:1190-1194.
19.
Levy ML, Aranda M., Zelman V., Giannotta SLPropylene glycol toxicity following continuous etomidate infusion for the control of refractory cerebral edema. Neurosurgery . 1995;37:363-369.
20.
Jacobi J., Fraser GL, Coursin DB, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med . 2002;30: 119-141.
21.
Salem MM, Mujais SKGaps in the anion gap. Arch Intern Med. 1992 ;152:1625-1629.
22.
Gennari FJCurrent concepts. serum osmolality. uses and limitations. N Engl J Med. 1984;310:102-105.
23.
Kay J., Chow WH, Chan TM, et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA. 2003;289:553-558.
24.
Barnes BJ, Gerst G., Smith JR, Terrell AR, Mullins MEOsmol gap as a surrogate marker for serum propylene glycol concentrations in patients receiving lorazepam for sedation. Pharmacotherapy . 2006;26:23-33.
25.
Giachetti C. , Zanolo G., Assandri A., Poletti P.Determination of cyclic butylboronate esters of some 1,2-and 2,3-diols in plasma by high-resolution gas chromatography/mass spectrometry. Biomed Environ Mass Spectrom. 1988;18: 592-597.
26.
Wilson KC, Reardon C., Theodore AC, Farber HWPropylene glycol toxicity: a severe iatrogenic illness in ICU patients receiving IV benzodiazepines: a case series and propspective, observaional pilot study . Chest. 2005; 128:1674-1681.
27.
Chicella M. , Jansen P., Parthiban A., et al. Propylene glycol accumulation associated with continuous infusion of lorazepam in pediatric intensive care patients . Crit Care Med. 2002 ;30:2752-2756.
28.
Christopher MM, Eckfeldt JH, Eaton JWPropylene glycol ingestion causes D-lactic acidosis. Lab Invest. 1990 ; 62:114-118.
29.
Speth PAJ , Vree TB, Neilen NFM , et al. Propylene glycol pharmacokinetics and effects after intravenous infusion in humans. Ther Drug Monit . 1987;9:255-258.
30.
Yu DK, Elmquist WF, Sawchuk RJPharmacokinetics of propylene glycol in humans during multiple dosing regimens . J Pharm Sci. 1985;74:876-879.
31.
Ruddick JAToxicology, metabolism, and biochemistry of 1,2-propanediol. Toxicol Appl Pharmacol. 1972;21: 102-111.
32.
Demey HE, Daelemans RA, Verpooten GA, et al. Propylene glycol-induced side effects during intravenous nitroglycerin therapy. Intensive Care Med. 1988;14:221-226.
33.
Bauer TM, Ritz R., Haberthur C., et al. Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet. 1995;346:145-147.
